NeoGenomics at Morgan Stanley conference: NGS, MRD drive growth

NeoGenomics reported 26% first-half 2026 NGS revenue growth, with its NGS portfolio exceeding $250 million in annualized revenue, while total clinical revenue rose about 14%. Medicare coverage for RaDaR ST in immunotherapy expands access to an estimated $4 billion portion of the roughly $20 billion MRD market, supporting a broader pan-cancer commercial strategy. Management expects NGS and MRD to rise from roughly one-third to more than half of the business over time, supporting mid-60%-plus margins, and continues to target full-year 2026 free-cash-flow positivity despite a Q3 DOJ settlement payment.

Analysis

NEO’s equity case is transitioning from a turnaround/revenue-cycle story to a mix-upgrade story, but the market will require proof that incremental revenue converts into durable EBITDA and cash flow rather than being absorbed by commercial and platform investment. The key earnings sensitivity is not headline test growth: it is sustained growth in large-panel utilization, clean reimbursement realization and lower cost per sample after the NovaSeq X conversion. If higher-value testing reaches a majority of revenue, a 500-1,000bp gross-margin expansion is plausible over 2-4 years; however, this is already partly embedded in a stock trading near its highs.

The principal competitive risk is that reimbursement validation attracts intensified selling by Natera (NTRA), Guardant Health (GH) and Exact Sciences (EXAS), whose MRD/liquid-biopsy franchises have larger installed bases and deeper clinical-evidence budgets. NEO’s community workflow positioning can reduce customer churn, but it can also create implementation risk: ordering automation and reflex testing must demonstrably increase paid tests without triggering payer denials, physician pushback, or elevated bad-debt expense. Xifin implementation is a near-term watch item, as billing-system conversions frequently create temporary claims disruption and working-capital volatility.

Near term, rising long-end yields are an important valuation headwind for unprofitable diagnostics equities: NEO needs execution beats to offset duration-driven multiple compression. Over the next 1-3 months, the investable catalyst is evidence that cash collections and revenue-cycle gains persist through the system transition; over 6-18 months, the decisive catalysts are MRD ordering adoption, additional coverage decisions, and evidence that sales-force investment produces volume growth rather than merely price/mix. Consensus may be over-crediting the stated MRD addressable market: coverage creates eligibility, not utilization, and oncology adoption tends to lag coverage until guidelines and real-world evidence catch up.

Key Decisions for Investors

• Maintain NEO as a watch-to-buy rather than chase at highs; initiate only on a 10-15% pullback or after the next earnings release confirms positive free cash flow excluding one-time items and no material deterioration in DSO/collections. Upside is meaningful if mix-led margin expansion is validated, but downside is 20%+ if the market re-rates it as a revenue-cycle beneficiary rather than a scalable diagnostics platform.
• For a 3-6 month relative-value expression, consider long NEO / short GH in equal dollar amounts only if NEO demonstrates sequential MRD order growth and stable gross margin. The thesis is that NEO’s community-channel cross-sell is underappreciated, while GH carries greater liquid-biopsy adoption and cash-burn sensitivity; exit if NEO’s clinical volume remains low-single-digit or GH delivers a major reimbursement/guideline win.
• Set a post-results alert on billing metrics: a sequential rise in receivables, DSO, denial rates, or cash conversion despite reported revenue growth would invalidate the near-term operating leverage thesis and warrant avoiding the long.
• Avoid treating ILMN as a direct hedge for NEO. NovaSeq X adoption may create a modest supplier benefit for ILMN, but the expenditure is too small relative to ILMN’s installed-base and China/research-demand exposures; the cleaner sector hedge for a long NEO is a short basket of high-duration diagnostics names rather than a single sequencing-equipment position.